Document is current
Any future updates will be listed below
-
Authors
Guijosa, Alberto
Tsakmaklis, Nicholas
Kobs, Margaret
Kofides, Amanda
Guerrera, Maria Luisa https://orcid.org/0000-0002-0730-4678
von Keudell, Gottfried
Branagan, Andrew https://orcid.org/0000-0002-3868-9267
Hunter, Zachary R. https://orcid.org/0000-0002-1689-1691
Treon, Steven P. https://orcid.org/0000-0001-6393-6154
Sarosiek, Shayna https://orcid.org/0000-0002-0075-6735
Castillo, Jorge J. https://orcid.org/0000-0001-9490-7532
- License Information
-
More Information
Article History
Received: 13 November 2025
Revised: 4 December 2025
Accepted: 27 January 2026
First Online: 3 February 2026
Competing interests
: JJC received research funds or consulting fees from AbbVie, AstraZeneca, BeOne, Cellectar, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, and Schrodinger. SS received research funding or consulting fees from ADC Therapeutics, AstraZeneca, BeOne, Cellectar, and Sobi. SPT received research funding, and/or consulting fees from Abbvie/Pharmacyclics Inc., Janssen Oncology Inc., Beigene Inc., Eli Lilly Pharmaceuticals, Bristol Myers Squibb, and Ono Pharmaceuticals.
: All methods were performed in accordance with the relevant guidelines and regulations governing human subjects research. The study was reviewed and approved by the Dana-Farber Cancer Institute Institutional Review Board (protocol number 25-151). Due to the retrospective nature of the study and the use of previously collected medical record data, the requirement for informed consent was waived.
